Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Nasopharyngeal specimens for culture of Chlamydia pneumoniae were obtained from patients with community-acquired pneumonia enrolled in a randomized study comparing the novel ketolide antibiotic ABT-773 at a dose of 150 mg once a day to 150 mg twice a day, by mouth for 10 days. C. pneumoniae was eradicated from the nasopharynx of 10 of 10 (100%) microbiologically evaluable patients. MICs and MBCs for 13 isolates of C. pneumoniae from 12 patients obtained before and after therapy were performed against ABT-773. The MIC90 and MBC90 of ABT-773 were 0.015 mg/L.
Hammerschlag
Margaret R
MR
Department of Pediatrics, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, New York, NY 11203-2098, USA. mhammerschlag@pol.net
Reznik
Tamara
T
Roblin
Patricia M
PM
Ramirez
Julio
J
Summersgill
James
J
Bukofzer
Stanley
S
D000328:Adult; D000368:Aged; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000187:drug effects; D004311:Double-Blind Method; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D048628:Ketolides; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009305:Nasopharynx / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D020133:Reverse Transcriptase Polymerase Chain Reaction
D048628:Ketolides; D004917:Erythromycin; C405499:cethromycin